Brind.
  1. AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.

M&A activity is driving sector recovery.

1 report, 1 independent Updated Jun 22
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

M&A activity is driving sector recovery.

Who's involved

What this event is mainly about
BiotechAbbVie

How it developed

Newest first. Tap a step to see who reported it.
  1. AbbVie reached a definitive agreement valued at $10.9 billion with Apogee Therapeutics.Sub-event
  2. High-level observation on the biotech sector's recovery driven by M&A activity.1 source

Keep exploring

Part of

AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.

Also in this story

All 3 developments

The entities involved

Coverage

Newest first; wire copies grouped